8-K: Seres Therapeutics Appoints Marella Thorell as CFO, David Arkowitz to Retire

Seres Therapeutics has announced the appointment of Marella Thorell as its new Chief Financial Officer, succeeding David Arkowitz who will retire, effective March 15, 2024.

Summary

• Seres Therapeutics has appointed Marella Thorell as Executive Vice President and Chief Financial Officer, effective on or about March 25, 2024.
• David Arkowitz, the current CFO, will retire effective March 15, 2024.
• Eric Shaff, the current President and CEO, will serve as interim principal financial officer and principal accounting officer until Ms. Thorell's start date.
• Ms. Thorell will receive an initial annual base salary of $480,000 and a one-time sign-on bonus of $80,000.
• She is also eligible for an annual discretionary bonus of up to 40% of her base salary.
• Ms. Thorell will receive an option to purchase 700,000 shares of the company's common stock, vesting over time.
• Mr. Arkowitz will receive twelve months of continued base salary and benefits, and will provide consulting services for six months at $500 per hour for up to ten hours per month.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a smooth executive transition with a qualified new CFO. However, it also acknowledges risks and uncertainties inherent in the business.

Positives

• Marella Thorell brings extensive experience in the life sciences and biotechnology industries, having held executive positions at Evelo Biosciences, Centessa Pharmaceuticals, Palladio Biosciences, and Realm Therapeutics.
• The transition plan includes a period of overlap where Mr. Arkowitz will be available to assist, ensuring a smooth handover.
• Ms. Thorell's experience includes leading finance operations and public company readiness activities, which could be beneficial for Seres.
• The company is actively commercializing VOWST and advancing SER-155, indicating ongoing business activity.

Negatives

• The departure of a key executive, David Arkowitz, could create some short-term uncertainty.
• The company is incurring costs associated with both the severance package for Mr. Arkowitz and the sign-on bonus for Ms. Thorell.

Risks

• The company acknowledges risks related to its financial performance, reliance on third parties, market acceptance of VOWST, competition, intellectual property protection, and retention of key personnel.
• The company has incurred significant losses and may not become profitable.
• The company's novel approach to therapeutic intervention carries inherent risks.

Future Outlook

The company is focused on the continued commercialization of VOWST and the advancement of SER-155, while also managing the executive transition.

Management Comments

• Eric Shaff stated he is excited to welcome Marella and looks forward to drawing from her extensive experience.
• Eric Shaff thanked David for his leadership and many valuable contributions.
• Marella Thorell stated she is thrilled to partner with the team at Seres and looks forward to applying her decades of experience to enhance shareholder value.
• David Arkowitz stated it has been a privilege to be part of the exciting journey at Seres and he is confident in the future success of the company.

Industry Context

The appointment of a new CFO is a common occurrence in the biotechnology industry, especially for companies in the commercialization phase. Ms. Thorell's experience in public and private companies aligns with Seres' current stage of development.

Comparison to Industry Standards

• The compensation package for Ms. Thorell, including base salary, bonus potential, and stock options, is generally in line with industry standards for CFOs at publicly traded biotechnology companies.
• The severance package for Mr. Arkowitz is also typical for executive departures, including continued salary and benefits.
• The use of an advisory agreement for a retiring executive is a common practice to ensure a smooth transition and retain institutional knowledge.
• Companies like Evelo Biosciences and Centessa Pharmaceuticals, where Ms. Thorell previously worked, are comparable in size and stage to Seres, suggesting her experience is directly relevant.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with extensive experience as positive.
• Employees may experience a change in leadership within the finance department.
• The transition is expected to be smooth, minimizing disruption to operations.

Next Steps

• Marella Thorell will commence her role as CFO on or about March 25, 2024.
• David Arkowitz will retire on March 15, 2024, and will provide consulting services for six months.
• The company will continue to focus on the commercialization of VOWST and the advancement of SER-155.

Key Dates

Keywords

CFO, Chief Financial Officer, executive transition, Marella Thorell, David Arkowitz, Seres Therapeutics, biotechnology, VOWST, SER-155, microbiome therapeutics